title: Frontal regional homogeneity increased and temporal regional homogeneity decreased after remission of first-episode drug-naïve major depressive disorder with panic disorder patients under duloxetine therapy for 6 weeks.
abstract: OBJECTIVE
  We designed this study to investigate the changes of regional homogeneity (ReHo) after a 6-week duloxetine therapy in first-episode drug-naïve major depressive disorder with panic disorder (FEMDDPD) patients.
  
  
  METHODS
  3T magnetic resonance imaging (MRI) scanning and ReHo functional MRI analysis were performed on 15 patients (male: 5; female: 10; age: 35.87±9.59 years old) at baseline and remitted status (sixth week) compared with 15 healthy control subjects (male: 4; female: 11; age: 34.30±9.87 years old) which were scanned twice within 6 weeks. The ReHo was analyzed by the REST toolbox (resting-state functional MRI data analysis toolbox). The ReHos of different time-points were compared by using paired t test function of REST.
  
  
  RESULTS
  ReHo increased in right superior frontal cortex, right medial frontal cortex and decreased in right superior temporal cortex (uncorrected p<0.00005, cluster threshold>20, surface connected theory) after remission of symptoms in these FEMDDPD patients within 6 weeks (improvements of clinician rating and self rating scale scores; post-hoc corrected p<0.001). No significant changes of ReHo were observed in the controls within 6 weeks (uncorrected p<0.1, no cluster threshold setting, surface connected theory). The changes of ReHo value were mildly correlated with improvements of clinical rating scales with age, gender, depression and anxiety severity as covariates.
  
  
  CONCLUSIONS
  Our study suggested that differential modulations inside the default mode network probably were associated with remission of FEMDDPD symptoms after duloxetine therapy.
authors.affiliation: Department of Psychiatry, Buddhist Tzu-Chi General Hospital, Taipei Branch, Taipei, Taiwan. t122336257@yahoo.com.tw
authors.forename: Chien-Han
authors.initials: CH
authors.lastname: Lai
authors.forename: Yu-Te
authors.initials: YT
authors.lastname: Wu
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000175:diagnosis* / Q000188:drug therapy*; D000068736:Duloxetine Hydrochloride; D005260:Female; D005625:Frontal Lobe / Q000473:pathology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000175:diagnosis* / Q000188:drug therapy*; D012074:Remission Induction; D013702:Temporal Lobe / Q000473:pathology*; D013876:Thiophenes / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride